TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34096500
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition during therapeutic hypothermia
Study: 34512511
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (target SBP 130-140 mmHg)
Study: 34512511
Drug: Guideline-recommended treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-recommended treatment (SBP <180 mmHg)
Study: 35979609
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg UDCA for 6 months
Study: 33976352
Drug: Carbon nanoparticle
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbon nanoparticle suspension
Study: 33601706
Drug: Next-intended antidepressant
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Next-intended antidepressant (AD) treatment with predicted moderate gene-drug interaction potential
Study: 33601706
Drug: Next-intended antidepressant
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Next-intended antidepressant (AD) treatment with predicted clinically significant gene-drug interaction potential
Study: 33601706
Drug: Previous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous treatment with an antidepressant (AD) in the past two years
Study: 35487576
Drug: CHO +
Normalized name: G-CSF (CHO cell derived)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO + BHB-ME (20 ± 2 g CHO and 590 mg/kg body mass β-hydroxybutyrate monoester)
Study: 35487576
Drug: CHO (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO (90 ± 9 g carbohydrate)
Study: 34870387
Drug: Accommodating variable-resistance
Normalized name: Ferric carbonate, ferric hydroxide, ferrous hydroxide (variable mixture)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accommodating variable-resistance exercise (AVr-Ex) program, 3 sessions/week over 8 weeks, in addition to usual physical therapy
Study: 34187220
Drug: Framing treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Framing treatment benefits in terms of loss (mortality)
Study: 32143733
Drug: Witnessed oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Witnessed oral informed consent (IC) prior to randomization and written IC after percutaneous coronary intervention for ST-segment elevation myocardial infarction patients.
Study: 32143733
Drug: Witnessed oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Witnessed oral informed consent (IC) prior to randomization and written IC before angiography for non-ST-segment elevation myocardial infarction patients.
Study: 32143733
Drug: Witnessed oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Witnessed oral informed consent (IC) process.
Study: 38178051
Drug: Sham manipulation
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham manipulation treatment
Study: 36328372
Drug: Ornidazole 1
Normalized name: ornidazole 167 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ornidazole 1 g orally 12 hours before surgery
Study: 35766258
Drug: Multifaceted intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multifaceted intervention including bedside delivery of P2Y12 inhibitor, education, automated reminder calls, and outreach for refill delays.
Study: 32338063
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg DBPR108
Study: 32338063
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg DBPR108
Study: 32338063
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg DBPR108
Study: 37290207
Drug: NEPA +
Normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NEPA + oral low-dose DEX (4 mg) on days 2-3 (DEX3)
Study: 37290207
Drug: NEPA +
Normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NEPA + standard DEX (4 mg twice daily) on days 2-4 (DEX4)
Study: 33896356
Drug: Secukinumab 300
Normalized name: secukinumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 300 mg/2 mL pre-filled syringe (PFS)
Study: 33641430
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg intravenous tranexamic acid (TXA) diluted in 100 ml normal saline (NS)
Study: 33641430
Drug: IV placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV placebo 100 ml normal saline (NS)
Study: 32124422
Drug: Multimodal intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multimodal intervention including adapted tango, music therapy, social activities, cognitive intervention, and psycho-education for 6 months.
Study: 33683710
Drug: Dexamethasone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (8 mg) and Ondansetron (4 mg)
Study: 32487507
Drug: 10 1-mg
Normalized name: cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 1-mg hydromorphone tablets or no hydromorphone if no opioids were required in hospital
Study: 32487507
Drug: 20 1-mg
Normalized name: baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 1-mg hydromorphone tablets (standard post-cesarean opioid prescription)
Study: 35935409
Drug: Tapered discontinuation
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tapered discontinuation of antipsychotic medication
Study: 32016928
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic Acid (TXA) - bolus dose of 10 mg/kg followed by 8 hours continuous infusion of 3 mg/kg/h
Study: 35102364
Drug: Gastric hop
Normalized name: HOPS
DrugBank: Hops (DB10687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastric hop extract (500 mg, quick-release capsules)
Study: 35102364
Drug: Duodenal hop
Normalized name: HOPS
DrugBank: Hops (DB10687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duodenal hop extract (500 mg, delayed-release capsules)
Study: 36203149
Drug: RTS,S/AS01E malaria
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS01E malaria vaccine (primary series and two seasonal boosters) and seasonal malaria chemoprevention (four monthly cycles per year)
Study: 36203149
Drug: RTS,S/AS01E malaria
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS01E malaria vaccine alone
Study: 36203149
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of SMC and RTS,S/AS01E
Study: 36240478
Drug: Rogaratinib (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rogaratinib (800 mg orally twice daily, 3-week cycles)
Study: 36240478
Drug: Chemotherapy (docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (docetaxel 75 mg/m2, paclitaxel 175 mg/m2, or vinflunine 320 mg/m2 intravenously once every 3 weeks)
Study: 36240478
Drug: Chemotherapy (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (in exploratory analysis)
Study: 34081408
Drug: Recombinant tetanus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant tetanus vaccine (TeNT-Hc 10/20/30 µg)
Study: 32387542
Drug: Tetanus toxoid
Normalized name: Tetanus Toxoid
DrugBank: Clostridium tetani toxoid antigen (formaldehyde inactivated) (DB10583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetanus toxoid (TT) vaccine
Study: 33268022
Drug: Sertraline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline plus Olanzapine
Study: 33268022
Drug: Sertraline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline plus Placebo
Study: 35488323
Drug: G-CBT +
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CBT + usual care
Study: 38975711
Drug: L-theanine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-theanine (200 mg)
Study: 34726760
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (annual alcohol and other drugs awareness training only)
Study: 34424869
Drug: Pregabalin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (2 mg/kg, twice daily preoperatively and for 5 days postoperatively)
Study: 32094154
Drug: Community intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community intervention programme (three monthly community clinics treating wet cough with prolonged antibiotics)
Study: 33676526
Drug: Ultra-congruent fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-congruent fixed (UC) implant
Study: 33676526
Drug: Low congruent
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low congruent fixed (CR DD) implant
Study: 33307633
Drug: Transversalis fascia
Normalized name: OCTINOXATE .012 mL in 6 mL / OCTISALATE .12 mL in 6 mL TOPICAL CREAM [RIMMEL LONDON MOISTURE RENEW LIPGLOSS - FUSCIA THERAPHY (345)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transversalis fascia plane (TFP) block with 0.4 mL/kg bupivacaine 0.25%
Study: 32325778
Drug: Omega-3 and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 and Vitamin D supplement (510 mg DHA, 344 mg EPA, 1000 IU vitamin D)
Study: 35419807
Drug: ASP8302 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP8302 (100 mg, oral, once daily for 4 weeks)
Study: 35139809
Drug: Group transdiagnostic
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group transdiagnostic cognitive-behavioural therapy (tCBT)
Study: 35139809
Drug: Individual transdiagnostic
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual transdiagnostic cognitive-behavioural therapy (tCBT)
Study: 32841683
Drug: Porcine liver
Normalized name: LIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Porcine liver decomposition product (PLDP) - 4 capsules for 4 weeks
Study: 32841683
Drug: Placebo -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - 4 capsules for 4 weeks
Study: 32281095
Drug: 1% lidocaine
Normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% lidocaine solution administered via new catheter
Study: 33958243
Drug: Butorphanol in
Normalized name: butorphanol Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol in combination with dexmedetomidine
Study: 32443302
Drug: Dexmedetomidine-ketamine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine-ketamine (1 mg/kg ketamine, 1 μg/kg dexmedetomidine loading dose over 10 minutes, followed by infusion at 0.6 μg/kg/h for 20 minutes)
Study: 32443302
Drug: Dexmedetomidine-fentanyl (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine-fentanyl (1 μg/kg fentanyl, 1 μg/kg dexmedetomidine loading dose over 10 minutes, followed by infusion at 0.6 μg/kg/h for 20 minutes)
Study: 32328824
Drug: G‐POEM (Gastric
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐POEM (Gastric peroral endoscopic myotomy)
Study: 34018344
Drug: Mesdopetam (IRL790)
Normalized name: Mesdopetam
DrugBank: Mesdopetam (DB16229)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesdopetam (IRL790) single dose (up to 120 mg)
Study: 34018344
Drug: Mesdopetam (IRL790)
Normalized name: Mesdopetam
DrugBank: Mesdopetam (DB16229)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesdopetam (IRL790) multiple doses (up to 80 mg)
Study: 32192396
Drug: Oral agar
Normalized name: Agar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral agar (600 mg/kg/day dissolved in 10 ml distilled water, twice daily until TSB decreased to 7 mg/dl)
Study: 32192396
Drug: Oral agar
Normalized name: Agar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral agar plus phototherapy
Study: 32694374
Drug: EtOH ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: EtOH ingestion (0.1 g·kg lean body mass·h; 30.2 ± 1.1 g 40% ABV Vodka)
Study: 35821785
Drug: Licaminlimab (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licaminlimab (60 mg/mL ophthalmic solution)
Study: 34345965
Drug: Viable probiotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viable probiotic tablets (Lactobacillus salivarius subsp. salicinius AP‐32, Bifidobacterium animalis subsp. lactis CP‐9, Lactobacillus paracasei ET‐66)
Study: 34345965
Drug: Heat-killed probiotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat-killed probiotic tablets (Lactobacillus salivarius subsp. salicinius AP‐32, Lactobacillus paracasei ET‐66)
Study: 34201821
Drug: Standard drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard drug supplementation of ferrous sulfate associated with folic acid
Study: 33572909
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CG) (n = 27) - continued daily lifestyle
Study: 36281668
Drug: Medication therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication therapy management
Study: 34537624
Drug: Intranasal vasopressin
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal vasopressin (AVP)
Study: 34919219
Drug: Atorvastatin (oral)
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin (oral) after surgery for at least 1 week
Study: 34919219
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no atorvastatin postoperatively)
Study: 34477217
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of traditional and modern recruitment methods
Study: 34106317
Drug: Oxymorphone (1.8,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymorphone (1.8, 3.2, 5.6, 10, 18, 32 mg/70 kg)
Study: 34106317
Drug: Hydromorphone (1.8,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone (1.8, 3.2, 5.6, 10, 18 mg/70 kg)
Study: 34106317
Drug: Oxycodone (18,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone (18, 32, 56 mg/70 kg)
Study: 34106317
Drug: Morphine (18,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (18, 32 mg/70 kg)
Study: 32383277
Drug: Assay-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assay-guided treatment (AGT; N=151)
Study: 32383277
Drug: Treatment-as-usual (TAU;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual (TAU; N=153)
Study: 33041038
Drug: 30 mL
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL of a 1:1 fish to flaxseed oil supplement in colostrum
Study: 33041038
Drug: 60 mL
Normalized name: Disposable Nurser 60 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mL of a 1:1 fish to flaxseed oil supplement in colostrum
Study: 33041038
Drug: 120 mL
Normalized name: 120 ML Infugem 10 MG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mL of a 1:1 fish to flaxseed oil supplement in colostrum
Study: 33041038
Drug: 0 mL
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mL of a 1:1 fish to flaxseed oil supplement in colostrum (control group)
Study: 33114566
Drug: Micronized lipid‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized lipid‐based carotenoid supplement, Lumega‐Z (LM)
Study: 33114566
Drug: PreserVision Age‐Related
Approvals — FDA: no, EMA: no, PMDA: no
Description: PreserVision Age‐Related Eye Disease Study 2 (AREDS‐2) soft gel (PV)
Study: 32677614
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (MMC) alone (0.1 mg/ml for 1 minute)
Study: 36089222
Drug: 0.5% EGCG/ethanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% EGCG/ethanol solutions
Study: 36131172
Drug: Heparin rota-flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin rota-flush solution
Study: 36131172
Drug: Traditional rota-flush
Normalized name: T8 Keto Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional rota-flush solution
Study: 32848380
Drug: tiotropium 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: tiotropium 5 µg
Study: 36036925
Drug: Vamorolone, 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vamorolone, 6 mg/kg per day
Study: 36036925
Drug: Vamorolone, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vamorolone, 2 mg/kg per day
Study: 36036925
Drug: Prednisone, 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone, 0.75 mg/kg per day
Study: 36036925
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (including vamorolone and prednisone)
Study: 35831153
Drug: Evolocumab 140
Normalized name: evolocumab 140 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab 140 mg every 2 weeks combined with atorvastatin 40 mg/day and ezetimibe 10 mg/day
Study: 35831153
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg/day and ezetimibe 10 mg/day (Control)
Study: 32135208
Drug: Dupilumab 300
Normalized name: dupilumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 300 mg every 2 weeks (adults)
Study: 32135208
Drug: Dupilumab 200
Normalized name: dupilumab 200 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 200 mg or 300 mg every 2 weeks (adolescents)
Study: 34215610
Drug: Implementation strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implementation strategy employing peer-led educational outreach, a clinical support tool, and peer support network to implement a TB treatment adherence intervention.
Study: 32194058
Drug: HAT therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAT therapy (hydrocortisone, ascorbic acid, thiamine)
Study: 35587064
Drug: Traditional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional physical therapy (control)
Study: 36045304
Drug: TLPLDC vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLPLDC vaccine
Study: 34517775
Drug: Potentially inappropriate
Normalized name: Potentilla discolor whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potentially inappropriate medication (PIM) use
Study: 32474584
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake inhibitors without appropriate indication
Study: 32474584
Drug: Proton-Pump Inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton-Pump Inhibitors (PPIs) without appropriate indication
Study: 35502947
Drug: Oral Cannabidiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Cannabidiol (CBD)
Study: 34342172
Drug: Apixaban 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban 0.5 mg IV
Study: 34342172
Drug: Apixaban 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban 1.25 mg IV
Study: 34342172
Drug: Apixaban 2.5
Normalized name: apixaban 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban 2.5 mg IV
Study: 34342172
Drug: Apixaban 3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban 3.75 mg IV
Study: 34342172
Drug: Apixaban 5
Normalized name: apixaban 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban 5 mg IV
Study: 34342172
Drug: Apixaban 5
Normalized name: apixaban 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban 5 mg oral
Study: 33232555
Drug: Placebo (glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (glucose syrup)
Study: 34916642
Drug: Conventional brain-guided
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional brain-guided (free-hand) implant surgery
Study: 34916642
Drug: Dynamic computer-assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic computer-assisted implant surgery (dCAIS)
Study: 34916642
Drug: Static computer-assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Static computer-assisted implant surgery (sCAIS)
Study: 34907003
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen (HBO2) therapy, ≥5 sessions (1 per day) for 90 minutes at 1.45 ATA for 7 days
Study: 34907003
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment for respiratory symptoms for 7 days
Study: 33443079
Drug: Clazakizumab (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clazakizumab (25 mg, 4-weekly subcutaneous injections for 12 weeks)
Study: 33443079
Drug: Clazakizumab (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clazakizumab (25 mg)
Study: 34063083
Drug: Intermittent fasting
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent fasting and glucose administration paired with relaxation and guided imagery
Study: 36054786
Drug: Jaktinib 100
Normalized name: Jaktinib
DrugBank: Jaktinib (DB17545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jaktinib 100 mg BID
Study: 36054786
Drug: Jaktinib 200
Normalized name: Jaktinib
DrugBank: Jaktinib (DB17545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jaktinib 200 mg QD
Study: 33614436
Drug: Intravenous methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous methadone
Study: 32001844
Drug: General requirements,
Approvals — FDA: no, EMA: no, PMDA: no
Description: General requirements, equipment, medicines and commodities, staffing and guidelines
Study: 35182045
Drug: Roxadustat 200
Normalized name: roxadustat
DrugBank: Roxadustat (DB04847)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Roxadustat 200 mg
Study: 35182045
Drug: Roxadustat 200
Normalized name: roxadustat
DrugBank: Roxadustat (DB04847)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Roxadustat 200 mg with simvastatin dosed 2 hours before, and 4 and 10 hours after
Study: 35182045
Drug: Roxadustat 200
Normalized name: roxadustat
DrugBank: Roxadustat (DB04847)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Roxadustat 200 mg with a statin
Study: 35182045
Drug: Roxadustat 200
Normalized name: roxadustat
DrugBank: Roxadustat (DB04847)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Roxadustat 200 mg with statins
Study: 32398131
Drug: Integrated microfinance-group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated microfinance-group medical visit model for NCD, involving monthly group medical visits led by a community health educator and a rural clinician, tested over a 6-month pilot.
Study: 33973398
Drug: Chiropractic care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiropractic care and Exercise therapy (combined)